| Trial ID: | L5989 |
| Source ID: | NCT01498900
|
| Associated Drug: |
Repaglinide
|
| Title: |
An Observational Study Evaluating Efficacy, Safety and Convenience of NovoNorm® in Treatment of Type 2 Diabetes in Routine Clinical Practice
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: repaglinide
|
| Outcome Measures: |
Primary: HbA1c (glycosylated haemoglobin) | Secondary: Fasting Plasma Glucose (FPG)|Postprandial glucose values|Incidence of hypoglycaemia|Adverse drug reactions (ADR)
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
30554
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2004-08
|
| Completion Date: |
2006-07
|
| Results First Posted: |
|
| Last Update Posted: |
2016-10-28
|
| Locations: |
Novo Nordisk Investigational Site, Istanbul, 34335, Turkey
|
| URL: |
https://clinicaltrials.gov/show/NCT01498900
|
